Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Market Acea Biosciences' Cell Assay Technology

NEW YORK (GenomeWeb News) – Roche Applied Science has licensed exclusive rights to market systems for real-time cell analysis based on Acea Biosciences’ impedance-based technology, the firms announced today.
The technology is being developed for applications including short-term kinetic analysis and for assays for cell proliferation, cytotoxicity, and cell migration and invasion. According to San Diego-based Acea, its technology offers a label-free system, real-time kinetics, live cell quality control, and high information content.
“After completing our product portfolio in DNA/RNA analysis with 454 and NimbleGen, the Acea technology will be an essential cornerstone to strengthen and further extend our product portfolio in cell analysis,” Manfred Baier, head of Roche Applied Science, said in a statement.
Financial terms of the agreement were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.